At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed prostate adenocarcinoma with plan for curative-intent radiation therapy
- ✓Lesion visible on prostate MRI and/or PSMA-PET/CT with concordant pathology from biopsy
- ✓Age ≥18 years
- ✓Signed informed consent and willing to comply with study procedures
- ✕Bilateral hip implants
- ✕Prior prostatectomy
- ✕Prior prostate cancer treatment including focal therapy (except hormone therapy started within 90 days prior to randomization)
- ✕Prior radiation therapy to area requiring treatment in present study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RAdiation Dose TAiloRing Guided by Enhanced Targeting
In Brief
A Phase 2 clinical trial evaluating Image-guided tumor-focused radiation therapy for Prostate Cancer. Currently recruiting, targeting 150 participants across 1 site.
Detailed Summary
This is a phase II non-blinded randomized controlled trial of image-guided, tumor-focused radiotherapy in patients with intermediate- or high-risk prostate cancer planning to undergo definitive radiotherapy with or without systemic therapy. The image-guided, tumor-focused radiotherapy will be compared to standard, whole-prostate treatment. The investigators hypothesize that tumor-focused radiotherapy reduces the radiation dose to organs close to the prostate, possibly leading to decreased acute toxicity to the genitourinary and gastrointestinal organs. The investigators will measure acute and late genitourinary and gastrointestinal toxicity due to radiation and regardless of cause. The investigators will also measure overall survival, metastasis-free survival, and quality of life, as well as biomarkers that may help predict, in the future, who may have a worse toxicity following radiation therapy.
Study Details
Timeline
Interventions
Image-guided tumor-focused radiation therapy